MY203765A - Chromosome conformation markers of prostate cancer and lymphoma - Google Patents
Chromosome conformation markers of prostate cancer and lymphomaInfo
- Publication number
- MY203765A MY203765A MYPI2021006427A MYPI2021006427A MY203765A MY 203765 A MY203765 A MY 203765A MY PI2021006427 A MYPI2021006427 A MY PI2021006427A MY PI2021006427 A MYPI2021006427 A MY PI2021006427A MY 203765 A MY203765 A MY 203765A
- Authority
- MY
- Malaysia
- Prior art keywords
- prostate cancer
- lymphoma
- markers
- chromosome conformation
- chromosome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/10—Detection mode being characterised by the assay principle
- C12Q2565/101—Interaction between at least two labels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1906487.2A GB201906487D0 (en) | 2019-05-08 | 2019-05-08 | DNA Marker |
| GB201914729A GB201914729D0 (en) | 2019-10-11 | 2019-10-11 | DNA marker |
| GBGB2006286.5A GB202006286D0 (en) | 2020-04-29 | 2020-04-29 | DNA marker |
| PCT/GB2020/051105 WO2020225551A1 (en) | 2019-05-08 | 2020-05-06 | Chromosome conformation markers of prostate cancer and lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY203765A true MY203765A (en) | 2024-07-17 |
Family
ID=70775424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2021006427A MY203765A (en) | 2019-05-08 | 2020-05-06 | Chromosome conformation markers of prostate cancer and lymphoma |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230049379A1 (enExample) |
| EP (1) | EP3966350A1 (enExample) |
| JP (2) | JP7617029B2 (enExample) |
| KR (1) | KR20220007132A (enExample) |
| CN (2) | CN114008218B (enExample) |
| AU (3) | AU2020268861B2 (enExample) |
| CA (1) | CA3138719A1 (enExample) |
| GB (3) | GB2626699B (enExample) |
| IL (1) | IL287597A (enExample) |
| MY (1) | MY203765A (enExample) |
| SG (1) | SG11202112221TA (enExample) |
| TW (1) | TWI873135B (enExample) |
| WO (1) | WO2020225551A1 (enExample) |
| ZA (1) | ZA202109658B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202302862A (zh) * | 2021-03-04 | 2023-01-16 | 英商牛津生物力學公眾有限公司 | 染色體交互作用標記物 |
| TW202548029A (zh) * | 2024-04-12 | 2025-12-16 | 英商牛津生物力學公眾有限公司 | 染色體標記測試 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101918831B (zh) * | 2007-11-08 | 2014-10-15 | 华盛顿大学 | 以dna微阵列为基础的平衡易位断点的鉴定和定位 |
| JP6666852B2 (ja) * | 2014-01-16 | 2020-03-18 | イルミナ インコーポレイテッド | 前立腺がん再発の予後に関する遺伝子発現パネル |
| CN108738329A (zh) * | 2015-05-29 | 2018-11-02 | 皇家飞利浦有限公司 | 前列腺癌预后方法 |
| US11795496B2 (en) * | 2015-06-24 | 2023-10-24 | Oxford BioDynamics PLC | Epigenetic chromosome interactions |
| WO2018100381A1 (en) * | 2016-12-01 | 2018-06-07 | Oxford Biodynamics Limited | Application of epigenetic chromsomal interactions in cancer diagnostics |
-
2020
- 2020-05-06 GB GB2406403.2A patent/GB2626699B/en active Active
- 2020-05-06 US US17/609,273 patent/US20230049379A1/en active Pending
- 2020-05-06 AU AU2020268861A patent/AU2020268861B2/en active Active
- 2020-05-06 CN CN202080044081.9A patent/CN114008218B/zh active Active
- 2020-05-06 MY MYPI2021006427A patent/MY203765A/en unknown
- 2020-05-06 KR KR1020217040317A patent/KR20220007132A/ko active Pending
- 2020-05-06 GB GBGB2117415.6D patent/GB202117415D0/en active Pending
- 2020-05-06 CA CA3138719A patent/CA3138719A1/en active Pending
- 2020-05-06 EP EP20726912.7A patent/EP3966350A1/en active Pending
- 2020-05-06 WO PCT/GB2020/051105 patent/WO2020225551A1/en not_active Ceased
- 2020-05-06 SG SG11202112221TA patent/SG11202112221TA/en unknown
- 2020-05-06 CN CN202510697824.7A patent/CN120591403A/zh active Pending
- 2020-05-06 GB GB2117415.6A patent/GB2597895B/en active Active
- 2020-05-06 JP JP2021566070A patent/JP7617029B2/ja active Active
- 2020-05-07 TW TW109115266A patent/TWI873135B/zh active
-
2021
- 2021-10-26 IL IL287597A patent/IL287597A/en unknown
- 2021-11-26 ZA ZA2021/09658A patent/ZA202109658B/en unknown
- 2021-12-14 AU AU2021286283A patent/AU2021286283B2/en active Active
- 2021-12-14 AU AU2021286282A patent/AU2021286282B2/en active Active
-
2024
- 2024-12-04 JP JP2024211835A patent/JP2025032205A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB2597895B (en) | 2024-09-11 |
| JP7617029B2 (ja) | 2025-01-17 |
| JP2022532108A (ja) | 2022-07-13 |
| WO2020225551A1 (en) | 2020-11-12 |
| TWI873135B (zh) | 2025-02-21 |
| ZA202109658B (en) | 2022-08-31 |
| GB2626699B (en) | 2024-11-20 |
| CN120591403A (zh) | 2025-09-05 |
| AU2021286283B2 (en) | 2022-04-07 |
| CA3138719A1 (en) | 2020-11-12 |
| EP3966350A1 (en) | 2022-03-16 |
| GB202406403D0 (en) | 2024-06-19 |
| CN114008218A (zh) | 2022-02-01 |
| AU2021286283A1 (en) | 2022-01-06 |
| AU2020268861A1 (en) | 2021-11-25 |
| TW202108773A (zh) | 2021-03-01 |
| GB2597895A (en) | 2022-02-09 |
| KR20220007132A (ko) | 2022-01-18 |
| AU2021286282A1 (en) | 2022-01-06 |
| SG11202112221TA (en) | 2021-12-30 |
| AU2021286282B2 (en) | 2022-04-07 |
| IL287597A (en) | 2021-12-01 |
| GB2626699A (en) | 2024-07-31 |
| CN114008218B (zh) | 2025-06-06 |
| GB202117415D0 (en) | 2022-01-19 |
| AU2020268861B2 (en) | 2022-02-03 |
| US20230049379A1 (en) | 2023-02-16 |
| JP2025032205A (ja) | 2025-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4549582A3 (en) | Methods for spatial analysis using targeted rna depletion | |
| PH12018502048A1 (en) | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer | |
| MX382562B (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub). | |
| MX2023013912A (es) | Metodos para inhibir ras. | |
| WO2020051142A3 (en) | Methods of treating cancer | |
| AU2015205612A8 (en) | Method for generating double stranded DNA libraries and sequencing methods for the identification of methylated cytosines | |
| EP3352761A4 (en) | METHOD FOR THE TREATMENT OF MALIGNEM RHABDOIDEM TUMOR OF OVARIA (MRTO) / SMALL CELL CARCINOMA OF THE HYPER-CALCEMIC TYPE OVARIA (SCCOHT) WITH AN EZH2 INHIBITOR | |
| DE602006002809D1 (de) | Verfahren zur erkennung eines ovarialkarzinoms | |
| MX2009008461A (es) | Variantes geneticas que contribuyen a riesgo de cancer de prostata. | |
| HK1219763A1 (zh) | 用於癌症预後的组合物和方法 | |
| EP3686290A3 (en) | Method and kits for identifying of cdk9 inhibitors for the treatment of cancer | |
| MX2019007332A (es) | Péptidos indicadores y métodos para caracterizar sensibilidad. | |
| MX390435B (es) | Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20. | |
| EP4202441A3 (en) | Gene expression profile in macrophages for the diagnosis of cancer | |
| EP4513187A3 (en) | Methods of detecting prostate cancer | |
| MX2019011017A (es) | Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii. | |
| MY200184A (en) | Biomarker | |
| MX2024001888A (es) | Composiciones y metodos para tratar linfoma difuso de celulas b grandes. | |
| EP3693742A3 (en) | Methods of detecting prostate cancer | |
| WO2020033019A3 (en) | Novel mct4 inhibitors and uses thereof | |
| PH12019501918A1 (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| CA2934815C (en) | Genetic markers associated with suicide risk and methods of use thereof | |
| EP4397652A3 (en) | 3-(phenyl)-2-(aminomethyl)-1-phenyl-2-propen-1-one derivatives as inhibitors of the n-terminal domain of the androgen receptor for treating prostate cancer | |
| ZA202109658B (en) | Chromosome conformation markers of prostate cancer and lymphoma | |
| EP3830134A4 (en) | COMPOSITIONS AND METHODS FOR DETECTING PROSTATE CANCER |